05/16. SEC warns on pot stocks. Writing has been on the

New Post Public Reply Private Reply Replies (0) Message Board
bellsandwhistles
05/16. SEC warns on pot stocks. Writing has been on the wall and couldn't be clearer. It's therefore prudent to examine pot-stock portfolios carefully for potential targets where red flags, funny numbers and questionable claims are evident, especially, among the dark firms not reporting to the SEC. There's a recently created and active 26-member SEC MFTF mentioned in this press release. This task force has pot stocks in their cross hairs. Lest we forget, MMJ is still federally illegal, and the heavy hand of Big Pharma may also weigh. The SEC never gives any warning to a targeted firm before a trading suspension.

"Spearheaded by its Microcap Fraud Task Force, the SEC Enforcement Division scours the microcap market and proactively identifies companies with publicly disseminated information that appears inadequate or potentially inaccurate. The SEC has the authority to issue trading suspensions against such companies while the questionable activity is further investigated."

Press Release

SEC Warns Investors About Marijuana-Related Investments Amid Recent Trading Suspensions

FOR IMMEDIATE RELEASE
2014-99

Washington D.C., May 16, 2014 —

The Securities and Exchange Commission today cautioned investors about the potential for fraud in microcap companies that claim their operations relate to the marijuana industry after the agency suspended trading in the fifth such company within the past two months.

The SEC issued an investor alert warning about possible scams involving marijuana-related investments, noting that fraudsters often exploit the latest growth industry to lure investors with the promise of high returns. “For marijuana-related companies that are not required to report with the SEC, investors may have limited information about the company’s management, products, services, and finances,” the SEC’s alert says. “When publicly available information is scarce, fraudsters can more easily spread false information about a company, making profits for themselves while creating losses for unsuspecting investors.”

Spearheaded by its Microcap Fraud Task Force, the SEC Enforcement Division scours the microcap market and proactively identifies companies with publicly disseminated information that appears inadequate or potentially inaccurate. The SEC has the authority to issue trading suspensions against such companies while the questionable activity is further investigated.

As the markets opened today, the SEC suspended trading in Denver-based FusionPharm Inc., which claims to make a professional cultivation system for use by cannabis cultivators among others. According to the SEC’s order, the trading suspension was issued “because of questions that have been raised about the accuracy of assertions by FusionPharm” concerning the company’s assets, revenues, financial statements, business transactions, and financial condition.

“Recent changes in state laws concerning medical and recreational marijuana have created new opportunities for penny stock fraud,” said Elisha Frank, co-chair of the SEC Enforcement Division’s Microcap Fraud Task Force. “Wherever we see incomplete or misleading disclosures, we act quickly to protect investors.”

Other marijuana-related companies in which the SEC recently suspended trading are Irvine, Calif.-based Cannabusiness Group Inc., Woodland Hills, Calif.-based GrowLife Inc., Colorado Springs-based Advanced Cannabis Solutions Inc., and Bedford, Texas-based Petrotech Oil and Gas Inc.

Under the federal securities laws, the SEC can suspend trading in a stock for 10 days and generally prohibit a broker-dealer from soliciting investors to buy or sell the stock again until certain reporting requirements are met. More information about the trading suspension process is available in an SEC investor bulletin on the topic.

“We know from experience that fraudsters follow the headlines,” said Lori J. Schock, director of the SEC’s Office of Investor Education and Advocacy, which prepared the investor alert. “Given the attention that marijuana-related companies have attracted recently, we urge investors to exercise caution when looking at investments in this space. Always thoroughly research the company – and the person selling the investment – before making a decision.”
###
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Understanding Adobe’s Recent Options Activity Results

Updated Category News Views 114

Adobe's Options Activity Highlights In the world of finance, significant trades often signal important market sentiments. Recently, major investors have moved toward a bearish outlook on Adobe. Analyzing the options history for Adobe (NASDAQ: ADBE), we've identified a total of 67 significant trades. Our insights reveal that approximately 41% of these trades have been...

Continue Reading
Indonesia's Ongoing Challenge with Chinese Maritime Presence

Updated Category News Views 130

Indonesia's Maritime Security Efforts Intensify Recently, Indonesia's maritime security has been under increased scrutiny as incidents involving a Chinese coast guard vessel continue to escalate. This week, a Chinese vessel was driven from Indonesian waters not once, but twice, after interfering with a critical energy survey conducted by Pertamina, the state energy...

Continue Reading
Revolutionizing Game Development with Upheaval Games' Dreamer Portal

Updated Category News Views 140

Welcome to the Future of Game Development Upheaval Games, founded by veterans from the gaming industry, embraces a new frontier in game design with the introduction of The Dreamer Portal. This innovative web-based interface allows creators to effortlessly build immersive game content with just a simple prompt. Imagine the power of crafting unique creatures, items, and...

Continue Reading
Alvotech Moves Forward with Gobivaz® Approval in Europe

Updated Category News Views 190

Alvotech and Advanz Pharma Collaborate for Biosimilar Approval REYKJAVIK and LONDON – Alvotech (NASDAQ: ALVO), a renowned biotechnology firm, along with Advanz Pharma, a leading global pharmaceutical company, has shared important news regarding the marketing approval of Gobivaz®, a proposed biosimilar to Simponi® (golimumab). This biologic treatment is designed for...

Continue Reading
Exploring the Growth Potential of Remote Patient Monitoring Sector

Updated Category News Views 181

Remote Patient Monitoring Set for Dynamic Growth The increasing prevalence of chronic conditions worldwide is expected to significantly accelerate the growth of the remote patient monitoring (RPM) market. As conditions like hypertension, diabetes, and cardiovascular diseases become more common, coupled with an aging population, healthcare systems face immense pressure to...

Continue Reading